[
  {
    "ts": null,
    "headline": "Pfizer Raises EPS Guidance and Expands Cost-Cutting Plan While Boosting Dividend Appeal",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the 13 Best Fortune 500 Dividend Stocks to Invest In. The company raises its Adjusted Diluted EPS guidance and raises its total savings goal amid a revenue increase in Q2 2025. Pfizer Inc. (NYSE:PFE)’s second-quarter results were reported on August 5, 2025, where it highlighted a year-over-year increase in […]",
    "url": "https://finnhub.io/api/news?id=692112058f9127d354771c2b0172f3b363d5ea932d2e69a65208fd0966e838eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758670801,
      "headline": "Pfizer Raises EPS Guidance and Expands Cost-Cutting Plan While Boosting Dividend Appeal",
      "id": 136858190,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the 13 Best Fortune 500 Dividend Stocks to Invest In. The company raises its Adjusted Diluted EPS guidance and raises its total savings goal amid a revenue increase in Q2 2025. Pfizer Inc. (NYSE:PFE)’s second-quarter results were reported on August 5, 2025, where it highlighted a year-over-year increase in […]",
      "url": "https://finnhub.io/api/news?id=692112058f9127d354771c2b0172f3b363d5ea932d2e69a65208fd0966e838eb"
    }
  },
  {
    "ts": null,
    "headline": "Viatris Inc. (VTRS) Gains FDA Approval for First Generic Iron Sucrose Injection",
    "summary": "In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Viatris Inc. is one of them. Viatris Inc. (NASDAQ:VTRS), formed from the 2020 merger of Mylan and Pfizer’s Upjohn division, delivers essential generic and specialty medicines to patients in over 165 countries. The company maintains […]",
    "url": "https://finnhub.io/api/news?id=3cbcf58d6c4183879602a2bc8af44d3464e42a4e1e6c4205dd9ece12fddfecd3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758669018,
      "headline": "Viatris Inc. (VTRS) Gains FDA Approval for First Generic Iron Sucrose Injection",
      "id": 136858191,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Viatris Inc. is one of them. Viatris Inc. (NASDAQ:VTRS), formed from the 2020 merger of Mylan and Pfizer’s Upjohn division, delivers essential generic and specialty medicines to patients in over 165 countries. The company maintains […]",
      "url": "https://finnhub.io/api/news?id=3cbcf58d6c4183879602a2bc8af44d3464e42a4e1e6c4205dd9ece12fddfecd3"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) Targets $4.5B in Cost Savings to Fuel R&D and Innovative Therapies",
    "summary": "In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Pfizer Inc. is one of them. Pfizer Inc. (NYSE:PFE), a global biopharmaceutical leader, continues to make strides in vaccines and oncology, reinforcing its position in the pharma sector. In September 2025, PFE and BioNTech reported […]",
    "url": "https://finnhub.io/api/news?id=bcd002c66c7b7dc998ef29a497eb613b96ec16be9e4c5389756378dbafa43abb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758669003,
      "headline": "Pfizer Inc. (PFE) Targets $4.5B in Cost Savings to Fuel R&D and Innovative Therapies",
      "id": 136858192,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Pfizer Inc. is one of them. Pfizer Inc. (NYSE:PFE), a global biopharmaceutical leader, continues to make strides in vaccines and oncology, reinforcing its position in the pharma sector. In September 2025, PFE and BioNTech reported […]",
      "url": "https://finnhub.io/api/news?id=bcd002c66c7b7dc998ef29a497eb613b96ec16be9e4c5389756378dbafa43abb"
    }
  },
  {
    "ts": null,
    "headline": "Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock?",
    "summary": "Making a major move in the obesity drug market, Pfizer (PFE) announced on Monday that it plans to acquire biotechnology firm Metsera (MTSR).",
    "url": "https://finnhub.io/api/news?id=54f4cd504bf42239ad333789ab57451e151f59893e508226cefb66f6d500d3c2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758668100,
      "headline": "Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock?",
      "id": 136858111,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Making a major move in the obesity drug market, Pfizer (PFE) announced on Monday that it plans to acquire biotechnology firm Metsera (MTSR).",
      "url": "https://finnhub.io/api/news?id=54f4cd504bf42239ad333789ab57451e151f59893e508226cefb66f6d500d3c2"
    }
  },
  {
    "ts": null,
    "headline": "Metsera (MTSR) Soars to All-Time High on $7.3-Billion Merger With Pfizer",
    "summary": "We recently published 10 Stocks Stealing Wall Street’s Spotlight. Metsera Inc. (NASDAQ:MTSR) is one of the top performers on Monday. Shares of Metsera Inc. (NASDAQ:MTSR) jumped to a new all-time high on Monday, as investors gobbled up shares following news that it was set to be acquired by Pfizer Inc. (NYSE: PFE) for a potential […]",
    "url": "https://finnhub.io/api/news?id=77a122a93b0a8a878e0d5c6956418af64672fee54e9b9a34bc3fa3eb81e34f04",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758651214,
      "headline": "Metsera (MTSR) Soars to All-Time High on $7.3-Billion Merger With Pfizer",
      "id": 136855600,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks Stealing Wall Street’s Spotlight. Metsera Inc. (NASDAQ:MTSR) is one of the top performers on Monday. Shares of Metsera Inc. (NASDAQ:MTSR) jumped to a new all-time high on Monday, as investors gobbled up shares following news that it was set to be acquired by Pfizer Inc. (NYSE: PFE) for a potential […]",
      "url": "https://finnhub.io/api/news?id=77a122a93b0a8a878e0d5c6956418af64672fee54e9b9a34bc3fa3eb81e34f04"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's $7.3B Gamble: Chasing Ozempic Rivals After Own Weight-Loss Pill Flopped",
    "summary": "The pharma giant is betting big on startup Metsera to claw its way back into the obesity drug race",
    "url": "https://finnhub.io/api/news?id=c9b0af6ba61e9ba4520a7f0238509d2db1239246331ef4da2e6486e5d3915e7f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758650012,
      "headline": "Pfizer's $7.3B Gamble: Chasing Ozempic Rivals After Own Weight-Loss Pill Flopped",
      "id": 136855601,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The pharma giant is betting big on startup Metsera to claw its way back into the obesity drug race",
      "url": "https://finnhub.io/api/news?id=c9b0af6ba61e9ba4520a7f0238509d2db1239246331ef4da2e6486e5d3915e7f"
    }
  },
  {
    "ts": null,
    "headline": "Can PFE Successfully Return to the Obesity Space With Metsera Buyout?",
    "summary": "Pfizer strikes a $4.9B deal for Metsera, adding obesity drug candidates to its pipeline after scrapping danuglipron.",
    "url": "https://finnhub.io/api/news?id=9a2ba6748f1ef7cb2b9739e59f5abfc8c9b43a062b5604ecf47fb0f655cc5775",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758644160,
      "headline": "Can PFE Successfully Return to the Obesity Space With Metsera Buyout?",
      "id": 136850972,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer strikes a $4.9B deal for Metsera, adding obesity drug candidates to its pipeline after scrapping danuglipron.",
      "url": "https://finnhub.io/api/news?id=9a2ba6748f1ef7cb2b9739e59f5abfc8c9b43a062b5604ecf47fb0f655cc5775"
    }
  },
  {
    "ts": null,
    "headline": "CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?",
    "summary": "CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.",
    "url": "https://finnhub.io/api/news?id=00c32a5b6191b94f9c25cd97dcf8efb8aee2328c71eb981a5babd46726d09320",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758638640,
      "headline": "CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?",
      "id": 136850973,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.",
      "url": "https://finnhub.io/api/news?id=00c32a5b6191b94f9c25cd97dcf8efb8aee2328c71eb981a5babd46726d09320"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts",
    "summary": "NEW YORK, September 23, 2025--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, November 4, 2025. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2025 Performance Report, to be issued that morning.",
    "url": "https://finnhub.io/api/news?id=e6cb11de50bad1f288007ac22b4b5761751efcd3e694c93e5ef19c0a83391b14",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758636000,
      "headline": "Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts",
      "id": 136850974,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, September 23, 2025--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, November 4, 2025. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2025 Performance Report, to be issued that morning.",
      "url": "https://finnhub.io/api/news?id=e6cb11de50bad1f288007ac22b4b5761751efcd3e694c93e5ef19c0a83391b14"
    }
  },
  {
    "ts": null,
    "headline": "This Hated Stock Suddenly Looks Like an Obesity Bargain",
    "summary": "Pfizer’s latest deal could make it the budget entry point to the weight-loss bonanza.",
    "url": "https://finnhub.io/api/news?id=7ecdd5182b6e8f7715ec43ddb4b17e33705785584c0bfe49734efb2f42abf830",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758619800,
      "headline": "This Hated Stock Suddenly Looks Like an Obesity Bargain",
      "id": 136850300,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer’s latest deal could make it the budget entry point to the weight-loss bonanza.",
      "url": "https://finnhub.io/api/news?id=7ecdd5182b6e8f7715ec43ddb4b17e33705785584c0bfe49734efb2f42abf830"
    }
  },
  {
    "ts": null,
    "headline": "Company News for Sep 23, 2025",
    "summary": "Companies In The News Are: ORCL, TAP, AAPL, MTSR, PFE.",
    "url": "https://finnhub.io/api/news?id=533f967195ae60351bb0f9e4970a81c2d2b7c8c5abacd25d1496d87e131d2e69",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758616500,
      "headline": "Company News for Sep 23, 2025",
      "id": 136850355,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Companies In The News Are: ORCL, TAP, AAPL, MTSR, PFE.",
      "url": "https://finnhub.io/api/news?id=533f967195ae60351bb0f9e4970a81c2d2b7c8c5abacd25d1496d87e131d2e69"
    }
  },
  {
    "ts": null,
    "headline": "The Ultimate Dividend King Drug Stock to Buy With $1,000 Right Now",
    "summary": "This out-of-favor industry could be in the doghouse for years. Do you buy for yield or for dividend safety?",
    "url": "https://finnhub.io/api/news?id=07af028eaf2964b65d3fc77e864e7c0e8cfbe733a628d5be86c69c76f0a18240",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758614700,
      "headline": "The Ultimate Dividend King Drug Stock to Buy With $1,000 Right Now",
      "id": 136850406,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "This out-of-favor industry could be in the doghouse for years. Do you buy for yield or for dividend safety?",
      "url": "https://finnhub.io/api/news?id=07af028eaf2964b65d3fc77e864e7c0e8cfbe733a628d5be86c69c76f0a18240"
    }
  },
  {
    "ts": null,
    "headline": "3 High-Yielding Dividend Stocks to Buy and Hold for the Long Haul -- Including United Parcel Service (UPS) and Pfizer",
    "summary": "Each of these dividend payers sports a fat yield of more than 6.5%.",
    "url": "https://finnhub.io/api/news?id=71e7127192483f8fc5d03923d42e3b88433373b886b2a666b901e4eed560851f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758614400,
      "headline": "3 High-Yielding Dividend Stocks to Buy and Hold for the Long Haul -- Including United Parcel Service (UPS) and Pfizer",
      "id": 136850978,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Each of these dividend payers sports a fat yield of more than 6.5%.",
      "url": "https://finnhub.io/api/news?id=71e7127192483f8fc5d03923d42e3b88433373b886b2a666b901e4eed560851f"
    }
  },
  {
    "ts": null,
    "headline": "What's Pfizer Getting in Its $7.3 Billion Metsera Buyout?",
    "summary": "Pfizer's plan to enter the booming obesity market took an expensive new turn.",
    "url": "https://finnhub.io/api/news?id=836ef027043e4ead86ac2004bb969d2076af5820682cbd8302ed7efe7d66d783",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758613620,
      "headline": "What's Pfizer Getting in Its $7.3 Billion Metsera Buyout?",
      "id": 136850979,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer's plan to enter the booming obesity market took an expensive new turn.",
      "url": "https://finnhub.io/api/news?id=836ef027043e4ead86ac2004bb969d2076af5820682cbd8302ed7efe7d66d783"
    }
  },
  {
    "ts": null,
    "headline": "Heard on the Street Tuesday Recap: Even Tylenol Can’t Cool This AI Fever",
    "summary": "Nvidia bet on OpenAI. The chip giant will invest up to $100 billion, allowing OpenAI to build data centers using Nvidia systems to train and run its next-generation models. Nvidia's shares rose 4%, adding nearly $170 billion to its market capitalization.",
    "url": "https://finnhub.io/api/news?id=f50051b696c5c8292296a6cc4d528a7d270286f25d279423026b21112b1711f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758609687,
      "headline": "Heard on the Street Tuesday Recap: Even Tylenol Can’t Cool This AI Fever",
      "id": 136850884,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Nvidia bet on OpenAI. The chip giant will invest up to $100 billion, allowing OpenAI to build data centers using Nvidia systems to train and run its next-generation models. Nvidia's shares rose 4%, adding nearly $170 billion to its market capitalization.",
      "url": "https://finnhub.io/api/news?id=f50051b696c5c8292296a6cc4d528a7d270286f25d279423026b21112b1711f0"
    }
  },
  {
    "ts": null,
    "headline": "Market Movers: Metsera and Apple surge, Kenvue falters on Tylenol troubles",
    "summary": "Here are the stocks that made the most news today.",
    "url": "https://finnhub.io/api/news?id=34d200941d73082f8377105158ab9a44e7f03315cc4b678a49776a9df281de58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758591690,
      "headline": "Market Movers: Metsera and Apple surge, Kenvue falters on Tylenol troubles",
      "id": 136850981,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Here are the stocks that made the most news today.",
      "url": "https://finnhub.io/api/news?id=34d200941d73082f8377105158ab9a44e7f03315cc4b678a49776a9df281de58"
    }
  }
]